Metabolic / GLP-1Semaglutide
GLP-1 receptor agonist
A GLP-1 receptor agonist with strong human and regulatory evidence, but approvals remain product-, population- and indication-specific.
Class AEvidence A
Read English overview →ENGLISH · RESEARCH LIBRARY
Search the evidence
not the claims
Each entry shows the molecule's pharmacology, regulatory class, evidence grade and a concise English evidence boundary.
HOW TO READ THE LIBRARY
Class describes regulatory or development context. Evidence Grade describes evidence strength; it is not a ranking of which molecule is better.
Metabolic / GLP-1Metabolic / GLP-1Tirzepatide
GIP and GLP-1 receptor agonist
A dual GIP/GLP-1 receptor agonist with strong clinical evidence; Mounjaro and Zepbound must be assessed as separate products and jurisdictions.
Class AEvidence A
Read English overview →Metabolic / GLP-1Retatrutide
GIP, GLP-1 and glucagon receptor agonist
An investigational triple GIP/GLP-1/glucagon receptor agonist with Phase 2 and Phase 3 research, but no marketing authorisation established in the reviewed jurisdictions.
Class BEvidence B
Read English overview →Metabolic / GLP-1Cagrilintide
Long-acting amylin analogue
A long-acting amylin analogue under clinical development; combination and monotherapy evidence should not be conflated.
Class BEvidence B
Read English overview →Metabolic / GLP-1Survodutide
Glucagon and GLP-1 receptor agonist
An investigational glucagon/GLP-1 receptor agonist studied in obesity and MASH; trial results are not the same as approval.
Class BEvidence B
Read English overview →Metabolic / GLP-1Mazdutide
Glucagon and GLP-1 receptor agonist
A glucagon/GLP-1 receptor agonist with jurisdiction-specific approval; status should not be transferred across countries or products.
Class AEvidence A
Read English overview →
Growth Hormone BiologyTesamorelin
Growth hormone-releasing factor analogue
A GHRH analogue with an approved, narrowly defined indication in some jurisdictions; this does not establish general fat-loss or anti-aging use.
Class AEvidence A
Read English overview →Growth Hormone BiologyIpamorelin
Growth hormone secretagogue / ghrelin-receptor agonist
A growth-hormone secretagogue with limited human evidence and no broad approved-use conclusion in the reviewed jurisdictions.
Class CEvidence C
Read English overview →Growth Hormone BiologyCJC-1295 with DAC
Long-acting growth hormone-releasing hormone analogue
A long-acting GHRH analogue studied mainly through pharmacodynamic endpoints; product identity and clinical benefit remain separate questions.
Class CEvidence C
Read English overview →Growth Hormone BiologyGHRP-2
Growth hormone-releasing peptide / ghrelin-receptor agonist
A ghrelin-receptor agonist with country- and indication-specific medicine history; endocrine responses do not establish broad clinical benefit.
Class AEvidence A
Read English overview →Growth Hormone BiologyGHRP-6
Growth hormone-releasing peptide / ghrelin-receptor agonist
A growth-hormone-releasing peptide with limited human research and no basis for broad performance or body-composition claims.
Class CEvidence C
Read English overview →Growth Hormone BiologySermorelin
Growth hormone-releasing hormone (GHRH 1-29) analogue
A GHRH(1-29) analogue with historical product approvals; current status and formulation require jurisdiction-specific verification.
Class AEvidence A
Read English overview →Growth Hormone BiologyHexarelin / Examorelin
Synthetic growth hormone-releasing hexapeptide / ghrelin-receptor agonist
An experimental growth-hormone secretagogue with early human research and no established broad therapeutic approval.
Class CEvidence C
Read English overview →
Tissue / Repair ResearchBPC-157
Experimental synthetic pentadecapeptide / mechanism not established
An experimental peptide supported mainly by preclinical research; animal tissue-repair findings do not establish human treatment efficacy.
Class CEvidence D
Read English overview →Tissue / Repair ResearchTB-500
Experimental synthetic heptapeptide fragment related to thymosin beta-4
A product term associated with thymosin beta-4 fragments; identity, sequence and evidence must not be assumed from the name alone.
Class CEvidence U
Read English overview →Tissue / Repair ResearchGHK-Cu
Copper(II)-binding tripeptide complex / tissue-remodelling research
A copper-binding tripeptide with route-specific evidence; topical cosmetic research does not establish injectable systemic benefit.
Class CEvidence C
Read English overview →Tissue / Repair ResearchKPV
Experimental melanocortin-derived tripeptide / anti-inflammatory research
A melanocortin-derived tripeptide with predominantly preclinical evidence and no established human therapeutic efficacy.
Class CEvidence E
Read English overview →Tissue / Repair ResearchARA-290 (Cibinetide)
Investigational erythropoietin-derived tissue-protective peptide
Also known as cibinetide, an investigational peptide studied in inflammatory and neuropathy contexts; clinical evidence remains indication-specific.
Class BEvidence C
Read English overview →
Mitochondrial / Metabolic ResearchElamipretide
Mitochondrial cardiolipin-binding tetrapeptide
A mitochondria-targeted peptide with product- and indication-specific regulatory status; approval in one context does not support wellness claims.
Class AEvidence A
Read English overview →Mitochondrial / Metabolic ResearchMOTS-c
Mitochondrial-derived 16-amino-acid peptide under clinical investigation
A mitochondrial-derived peptide with mainly preclinical and early human research; metabolic findings remain investigational.
Class BEvidence E
Read English overview →Mitochondrial / Metabolic ResearchNAD+
Endogenous redox cofactor and metabolic co-substrate; not a peptide
An endogenous redox cofactor, not a peptide; evidence depends strongly on precursor, formulation and route.
Class CEvidence C
Read English overview →Mitochondrial / Metabolic Research5-Amino-1MQ
Experimental small-molecule nicotinamide N-methyltransferase inhibitor; not a peptide
An experimental small-molecule NNMT inhibitor, not a peptide, with predominantly preclinical evidence.
Class CEvidence E
Read English overview →Mitochondrial / Metabolic ResearchAICAR (Acadesine)
Investigational purine nucleoside analogue / adenosine-regulating agent; not a peptide
A nucleoside analogue and AMPK-related research compound, not a peptide; clinical and anti-doping contexts must be separated.
Class BEvidence B
Read English overview →Mitochondrial / Metabolic ResearchSLU-PP-332
Experimental small-molecule ERRα/β/γ agonist; not a peptide
An experimental ERR agonist with preclinical-only evidence; animal exercise-mimetic findings do not establish human benefit.
Class CEvidence E
Read English overview →
Neuro / Cognitive ResearchSemax
Synthetic ACTH(4-10)-related heptapeptide without established corticotropic activity
An ACTH-fragment-related neuropeptide with country-specific product history; this is not equivalent to global approval.
Class AEvidence C
Read English overview →Neuro / Cognitive ResearchHumanin
Endogenous mitochondrial-derived peptide; synthetic Humanin and HNG analogues are experimental
An endogenous mitochondrial-derived peptide studied mainly in mechanistic and preclinical research, without established therapeutic efficacy.
Class CEvidence D
Read English overview →Neuro / Cognitive ResearchSelank
Synthetic tuftsin-related regulatory heptapeptide; registered nasal medicine in Russia
A tuftsin-related heptapeptide with Russia-specific product history and limited human evidence; it is not FDA-approved.
Class AEvidence C
Read English overview →Neuro / Cognitive ResearchDSIP (Emideltide)
Experimental nonapeptide historically studied in sleep and neuroendocrine research
A peptide associated with sleep research, but identity, study quality and clinical evidence remain limited and uncertain.
Class CEvidence C
Read English overview →Neuro / Cognitive ResearchPinealon (EDR)
Experimental synthetic tripeptide studied in neuroprotection, oxidative-stress and aging models
An experimental tripeptide studied mostly through preclinical and small human datasets; cognitive claims remain unestablished.
Class CEvidence D
Read English overview →
Longevity / Aging ResearchEpitalon
Experimental synthetic pineal-derived tetrapeptide
An experimental tetrapeptide with limited human evidence; cell or biomarker findings do not establish human lifespan extension.
Class CEvidence C
Read English overview →Longevity / Aging ResearchThymalin
Prescription bovine thymus-extract peptide complex registered in Russia; immunostimulant research and clinical use are jurisdiction-specific
A thymus-extract peptide complex with country-specific product history; it should not be treated as a single defined peptide.
Class AEvidence C
Read English overview →Longevity / Aging ResearchThymosin Alpha-1
Synthetic N-terminal acetylated 28-amino-acid immunomodulatory peptide
A synthetic immunomodulatory peptide with jurisdiction-specific medicine status and indication-bounded clinical evidence.
Class AEvidence B
Read English overview →IMPORTANT BOUNDARY
English summaries remain educational
They do not provide prices, purchasing, dosing, injection protocols, diagnosis or individual treatment advice. Regulatory status may change and must be checked against current official records.